Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo — use of the human tyrosinase promoter with human enhancers

Cancer Gene Therapy volume 12, pages 864–872 (2005)Cite this article

Abstract

Current treatment regimens for patients with metastatic melanoma are not curative, and new treatment strategies are needed. One possible approach is targeted treatment using the tyrosinase promoter for melanoma-specific expression of genes delivered by adenoviral (Ad) vectors. In this study, a vector with the human minimal tyrosinase promoter and two human enhancer elements (2hE-hTyrP) was compared with different hybrid promoter constructs, containing tyrosinase regulatory sequences and the viral simian virus 40 (SV40) promoter. The tissue specificity of the first-generation vectors was measured by enhanced green fluorescence protein (EGFP) reporter flow cytometry in 12 human melanoma and nonmelanoma cell lines. In the melanotic melanoma cells, the activity of the 2hE-hTyrP promoter was comparable with the activity of the cytomegalovirus promoter, and the background expression levels obtained in the nonmelanoma cell lines confirmed the strict tissue-specific property of this promoter. The hybrid SV40-based promoters were effective, but no tissue specificity was observed even after the inclusion of tyrosinase enhancer elements identical to the elements used in the 2hE-hTyrP promoter. The in vivo tissue specificity of the 2hE-hTyrP vector was demonstrated in subcutaneous xenografted tumors by ex vivo detection of EGFP fluorescence with the IVIS®Imaging equipment and fluorescence microscopy visualizing the in situ EGFP expression in tumor sections. The tyrosinase mRNA level in the 12 cell lines was measured by quantitative real-time RT-PCR, and the expression levels reliably reflected to what extent the 2hE-hTyrP promoter could drive the gene expression in the individual cell lines. In conclusion, the human tyrosinase promoter fused to two human tyrosinase enhancers (2hE-hTyrP) can be used for efficient tissue-specific expression from first-generation Ad vectors in melanoma cell lines both in vitro and in vivo, as predicted by the quantitative tyrosinase mRNA levels in the melanoma and nonmelanoma cell lines tested.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Nakamura T, Sato K, Hamada H . Effective gene transfer to human melanomas via integrin-targeted adenoviral vectors. Hum Gene Ther. 2002;13:613–626.

    Article  CAS  PubMed  Google Scholar 

  2. Nettelbeck D, Rivera AA, Kupsch J, et al. Retargeting of adenoviral infection to melanoma: combining genetic ablation of native tropism with a recombinant bispecific single-chain diabody (scDb) adapter that binds to fiber knob and HMWMAA. Int J Cancer. 2004;108:136–145.

    Article  CAS  PubMed  Google Scholar 

  3. Siders W, Halloran PJ, Fenton RG . Transcriptional targeting of recombinant adenoviruses to human and murine melanoma cells. Cancer Res. 1996;56:5638–5646.

    CAS  PubMed  Google Scholar 

  4. Nettelbeck DM, Jèrôme V, Müller R . Gene therapy — designer promoters for tumour targeting. Trends Genet. 2000;16:174–181.

    Article  CAS  PubMed  Google Scholar 

  5. Shi C-X, Hitt M, Ng P, Graham FL . Superior tissue-specific expression from tyrosinase and prostate-specific antigen promoters/enhancers in helper-dependent compared with first-generation adenoviral vectors. Hum Gene Ther. 2002;13:211–224.

    Article  PubMed  Google Scholar 

  6. Peter I, Graf C, Dummer R, Schaffner W, Greber UF, Hemmi S . A novel attenuated replication-competent adenovirus for melanoma therapy. Gene Therapy. 2003;10:530–539.

    Article  CAS  PubMed  Google Scholar 

  7. Nettelbeck D, Jerome V, Müller R . A dual specificity promoter system combining cell cycle-regulated and tissue-specific transcriptional control. Gene Therapy. 1999;6:1276–1281.

    Article  CAS  PubMed  Google Scholar 

  8. Park BJB, CK A, Hu Y, et al. Augmentation of melanoma-specific gene expression using a tandem melanocyte-specific enhancer results in increased cytotoxicity of the purine nucleoside phosphorylase gene in melanoma. Hum Gene Ther. 1999;10:889–898.

    Article  CAS  PubMed  Google Scholar 

  9. Nettelbeck D, Rivera AA, Balaguè C, Alemany R, Curiel DT . Novel oncolytic adenovirus targeted to melanoma; specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. Cancer Res. 2002;62:4663–4670.

    CAS  PubMed  Google Scholar 

  10. Zhang L, Akbulut H, Tang Y, et al. Adenoviral vectors with E1A regulated by tumor-specific promoters are selectively cytotoxic for breast cancer and melanoma. Mol Ther. 2002;6:386–393.

    Article  CAS  PubMed  Google Scholar 

  11. Liu Y, Ye T, Sun D, Maynard J, Deisseroth A . Conditionally replication-competent adenoviral vectors with enhanced infectivity for use in gene therapy of melanoma. Hum Gene Ther. 2004;15:637–647.

    Article  CAS  PubMed  Google Scholar 

  12. Banerjee N, Rivera AA, Wang M, et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter driven E1A, E4, or both in submerged cells and organotypic cultures. Mol Cancer Ther. 2004;3:437–449.

    CAS  PubMed  Google Scholar 

  13. Fodstad O, Kjonniksen I, AAmdal S, Nesland JM, Boyd MR, Pihl A . Extrapulmonary, tissue-specific metastasis formation in nude mice injected with FEMX-I human melanoma cells. Cancer Res. 1988;48:4382–4388.

    CAS  PubMed  Google Scholar 

  14. AAmdal SFO, Pihl A . Human tumor xenografts transplanted under the renal capsule of conventional mice. Growth rates and host immune response. Int J Cancer. 1984;34:725,730.

    Article  Google Scholar 

  15. Kjonniksen IRP, Fodstad O . Helix pomatia agglutinin binding in human tumor cell lines: correlation with pulmonary metastases in nude mice. J Cancer. 1994;69:1021–1024.

    Article  CAS  Google Scholar 

  16. Fodstad O, Aamdal S, McMenamin M, Nesland JM, Pihl A . A new experimental metastasis model in athymic nude mice, the human malignant melanoma LOX. Int J Cancer. 1988;41:442–449.

    Article  CAS  PubMed  Google Scholar 

  17. Fodstad O, Brogger A, Bruland O, Solheim OP, Nesland JM, Pihl A . Characteristics of a cell line established from a patient with multiple osteosarcoma, appearing 13 years after treatment for bilateral retinoblastoma. Int J Cancer. 1986;38:33–40.

    Article  CAS  PubMed  Google Scholar 

  18. He T-C, Zhou S, Da Costa LT, Yu J, Kinzler KW, Vogelstein B . A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA. 1998;95:2509–2514.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Shariatmadari R, Sipila PP, Huhtaniemi IT, Poutanen M . Improved technique for detection of enhanced green fluorescent protein (EGFP) in transgenic mice. BioTechniques. 2001;30:1282–1285.

    Article  CAS  PubMed  Google Scholar 

  20. Diaz R, Eisen T, Hart IR, Vile RG . Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J Virol. 1998;72:789–795.

    CAS  PubMed  PubMed Central  Google Scholar 

  21. Brooks ARHR, Wang P, Qian HS, Liu P, Rubanyi GM . Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle. J Gene Med. 2004;6:395–404.

    Article  CAS  PubMed  Google Scholar 

  22. Papadakis EDNS, Baker AH, White SJ . Promoters and control elements: designing expression cassettes for gene therapy. Curr Gene Ther. 2004;4:89–113.

    Article  CAS  PubMed  Google Scholar 

  23. Gaggioli CBR, Abbe P, Ortonne J-P, Ballotti R . Microphtalmia-associated transcription factor (MITF) is required but is not sufficient to induce the expression of melanogenic genes. Pigment Cell Res. 2003;16:374–382.

    Article  CAS  PubMed  Google Scholar 

  24. Okada Y, Okada N, Nakagawa S, et al. Tumor necrosis factor alpha-gene therapy for an established murine melanoma using RGD (Arg-Gly-Asp) fiber-mutant adenovirus vectors. Jpn J Cancer Res. 2002;93:436–444.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

We are grateful to Dr Richard G Vile for providing us with the pGL3-3hTDE-SV40-EGFP plasmid. The Norwegian Radium Hospital, The Norwegian Cancer Society, Anna Lovise Lundeby Memorial Fund and Gene Therapy Funding from the Norwegian Ministry of Health supported this work.

Author information

Authors and Affiliations

  1. Department of Tumor Biology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway

    Trine Lillehammer, Siri Tveito, Birgit O Engesaeter, Oystein Fodstad, Gunhild M Maelandsmo & Olav Engebraaten

  2. Department of Oncology, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway

    Olav Engebraaten

  3. Faculty Division, The Norwegian Radium Hospital, University of Oslo, Oslo, Norway

    Oystein Fodstad & Olav Engebraaten

Authors
  1. Trine Lillehammer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Siri Tveito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Birgit O Engesaeter
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Oystein Fodstad
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gunhild M Maelandsmo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Olav Engebraaten
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Trine Lillehammer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lillehammer, T., Tveito, S., Engesaeter, B. et al. Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo — use of the human tyrosinase promoter with human enhancers. Cancer Gene Ther 12, 864–872 (2005). https://doi.org/10.1038/sj.cgt.7700852

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700852

Keywords

This article is cited by

Search

Advanced search

Quick links